Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of 2024All-stock merger of equals transaction with Ceapro Inc. expected to close in the second quarter of 2024 TORONTO, ONTARIO, May 14, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ Registration Statement Pursuant to Section 12(b) or 12(g) of The Securities Exchange Act of 1934 OR ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 OR ☐ Shell Company Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Commis ...

Exhibit 99.1 Aeterna Zentaris Inc. Consolidated Financial Statements As of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021 Report of Independent Registered Public Accounting Firm (PCAOB ID:1208) 2 Report of Predecessor Independent Registered Public Accounting Firm (PCAOB ID:1263) 4 Consolidated Statements of Financial Position 5 Consolidated Statements of Changes in Shareholders’ Equity 6 Consolidated Statements of Loss and Comprehensive Loss 7 Consolidated Statements of ...

TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro") are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the "Transaction") at their respective special meetings held today. The specific voting results were as follows: Aeterna shareholders approved the Transaction with the following voting results: Resol ...

ISS states in its Aeterna Zentaris FOR recommendation that "on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably managed."ISS states in its Ceapro FOR recommendation that "The arrangement is the result of arm's length negotiations between the parties and carries sound strategic logic."Aeterna Zentaris and Ceapro securityholders are encouraged to vote well in advance of the prox ...

Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available at www.AEZSmerger.comShareholders with questions or who require assistance voting their shares should contact Kingsdale Advisors at 1-866-581-1513 (North American Toll Free) or 416-623-2513 (outside North America – text and call enabled) or contactus@kingsdaleadvisors.com TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) ...

Exhibit 99.1 Aeterna Zentaris Inc. Condensed Interim Consolidated Financial Statements As of September 30, 2023, and for the three and nine months ended September 30, 2023, and 2022 (In thousands of US dollars) (Unaudited) Condensed Interim Consolidated Statements of Financial Position 2 Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity 3 Condensed Interim Consolidated Statements of Loss and Comprehensive Loss 4 Condensed Interim Consolidated Statements of Cash Flows 5 Notes to Co ...

Exhibit 99.1 Aeterna Zentaris Inc. Condensed Interim Consolidated Financial Statements As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022 (In thousands of US dollars) (Unaudited) Condensed Interim Consolidated Statements of Financial Position 2 Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity 3 Condensed Interim Consolidated Statements of Loss and Comprehensive Loss 4 Condensed Interim Consolidated Statements of Cash Flows 5 Notes to Condensed Int ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ Registration Statement Pursuant to Section 12(b) or 12(g) of The Securities Exchange Act of 1934 OR ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 OR ☐ Shell Company Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Commis ...

Exhibit 99.1 Aeterna Zentaris Inc. Consolidated Financial Statements As of December 31, 2022 and 2021 and for the years ended December 31, 2022, 2021 and 2020 Report of Independent Registered Public Accounting Firm (PCAOB ID:1263) 2 Report of Predecessor Independent Registered Public Accounting Firm (PCAOB ID:271) 4 Consolidated Statements of Financial Position 5 Consolidated Statements of Changes in Shareholders’ Equity 6 Consolidated Statements of Loss and Comprehensive Loss 7 Consolidated Statements of C ...